UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Form 8-K

CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported)

December 6, 2016

Commission File Number: 001-36568

HEALTHEQUITY, INC.

Delaware

(State or other jurisdiction of incorporation or organization)

7389 (Primary Standard Industrial

Člassification Code Number) 15 West Scenic Pointe Drive Suite 100 52-2383166

(I.R.S. Employer Identification Number)

Suite 100 Draper, Utah 84020 (801) 727-1000

(Address, including Zip Code, and Telephone Number, including Area Code, of Registrant's Principal Executive Offices)

Not Applicable (Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2):

□ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

□ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

□ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

□ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 2.02 Results of Operations and Financial Condition

On December 6, 2016, HealthEquity, Inc. issued a press release announcing its financial results for its third quarter ended October 31, 2016. The full text of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

This information is intended to be furnished under Item 2.02 of Form 8-K, "Results of Operations and Financial Condition" and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.

Item 9.01 Financial Statements and Exhibits

(d) Exhibits

Exhibit No. Description

99.1 Press release issued by HealthEquity, Inc. dated December 6, 2016, announcing financial results for its third quarter ended October 31, 2016.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

HEALTHEQUITY, INC.

Date: December 6, 2016

| By: | /s/ Darcy Mott |
|--------|---|
| Name: | Darcy Mott |
| Title: | Executive Vice President and Chief Financial Officer |

| Exhibit | |
|---------|---|
| no. | Description |
| 99.1 | Press release issued by HealthEquity, Inc. dated December 6, 2016, announcing financial results for its third quarter ended October 31, 2016. |

HealthEquity Reports Third Quarter Ended October 31, 2016 Financial Results

Highlights of the third quarter include:

- Revenue of \$43.4 million, an increase of 42% compared to Q3 FY16.
- Net income of \$6.0 million, an increase of 47% compared to Q3 FY16.
- Net income per diluted share of \$0.10, compared to \$0.07 in Q3 FY16.
- Adjusted EBITDA of \$14.5 million, an increase of 47% compared to Q3 FY16.
- HSA Members grew to 2.4 million, an increase of 48% compared to Q3 FY16.
- Total AUM grew to \$4.3 billion, an increase of 59% compared to Q3 FY16.

Draper, Utah – December 6, 2016 – HealthEquity, Inc. (NASDAQ: HQY), one of the largest health savings account ("HSA") non-bank custodians, today announced financial results for its third quarter ended October 31, 2016.

"Our third quarter results continued to build on our record-setting year which has increased total HSA Members by more than 776,000 since the end of the third quarter last year. Total AUM has grown by nearly \$1.6 billion, or 59%, over that same time frame," remarked Jon Kessler, President and CEO of HealthEquity. "The growth in these base metrics of our business has driven a consistently strong performance from all three of our revenue streams. Our year-over-year revenue growth of 42% in the quarter continues to outpace the industry, and our Adjusted EBITDA growth of 47% demonstrates our ability to continue to scale profitability our business."

Third quarter financial results

For the third quarter ended October 31, 2016, HealthEquity reported revenue of \$43.4 million, compared to \$30.6 million for the third quarter ended October 31, 2015, an increase of 42%. Revenue consisted of:

- Service revenue of \$18.8 million, an increase of 24% compared to Q3 FY16.
- Custodial revenue of \$15.0 million, an increase of 64% compared to Q3 FY16.
- Interchange revenue of \$9.6 million, an increase of 55% compared to Q3 FY16.

Net income was \$6.0 million for the third quarter ended October 31, 2016, compared to \$4.1 million for the third quarter ended October 31, 2015.

Net income per diluted share was \$0.10 for the third quarter ended October 31, 2016, compared to \$0.07 for the third quarter ended October 31, 2015.

Adjusted EBITDA was \$14.5 million for the third quarter ended October 31, 2016, an increase of 47% compared to \$9.9 million for the third quarter ended October 31, 2015. Adjusted EBITDA was 34% of revenue for the third quarter ended October 31, 2016, compared to 32% for the third quarter ended October 31, 2015.

As of October 31, 2016, we had \$165.7 million of cash, cash equivalents and marketable securities and no outstanding debt. This compares to \$123.8 million in cash, cash equivalents and marketable securities and no outstanding debt as of January 31, 2016.

HSA Member and AUM metrics

The total number of HSAs for which we serve as a non-bank custodian ("HSA Members") as of October 31, 2016 was 2.4 million, an increase of 48% from 1.6 million as of October 31, 2015.

Total assets under management ("AUM") as of October 31, 2016 was \$4.3 billion, an increase of 59% year over year, comprised of:

- Cash AUM of \$3.7 billion, an increase of 61% compared to Q3 FY16; and
- Investment AUM of \$570.6 million, an increase of 48% compared to Q3 FY16.

Business outlook

For the year ended January 31, 2017, we are reaffirming our previously provided guidance. Our revenue outlook is a range of \$174.0 million to \$178.0 million. Our outlook for net income is a range of \$23.0 million to \$25.0 million, resulting in a net income per diluted share range of \$0.38 to \$0.42 (based on an estimated 60.0 million weighted-average shares outstanding). Our Adjusted EBITDA outlook is a range of \$59.0 million to \$62.0 million. The business outlook for the year ended January 31, 2017 assumes a projected effective tax rate of approximately 36%.

A reconciliation of the non-GAAP financial measures used throughout this release to the most comparable GAAP financial measures is included with the financial tables at the end of this release.

Conference call

HealthEquity management will host a conference call at 5:00 pm (Eastern Time) on Tuesday, December 6, 2016 to discuss the third quarter financial results. The conference call will be accessible by dialing 844-791-6252, or 661-378-9636 for international callers, and referencing conference ID 12268124. A live webcast of the conference call will also be available on the investor relations section of our website at www.HealthEquity.com.

A replay of the conference call will be made available for 30 days on our website at ir.healthequity.com

Non-GAAP financial information

To supplement our financial information presented on a GAAP basis, we disclose Adjusted EBITDA, which is a non-GAAP financial measure. We define Adjusted EBITDA as earnings before interest, taxes, depreciation and amortization, stock-based compensation expense, and other certain non-operating items.

Non-GAAP financial measures should be considered in addition to results prepared in accordance with GAAP and should not be considered as a substitute for, or superior to, GAAP results. The company cautions investors that non-GAAP financial information, by its nature, departs from traditional accounting conventions; accordingly, its use can make it difficult to compare current results with results from other reporting periods and with the results of other companies. Whenever we use non-GAAP financial measures, we provide a reconciliation of the applicable non-GAAP financial measure to the most comparable GAAP financial measure. Investors are encouraged to review the related GAAP financial measures and the reconciliation of the non-GAAP financial measures to the most comparable GAAP financial measures as detailed in the tables below.

Forward-Looking Statements

This press release contains "forward-looking statements" within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995, including but not limited to, statements regarding the company's industry, business strategy, plans, goals and expectations concerning the company's market position, product expansion, future operations, revenue, margins, profitability, future efficiencies, capital expenditures, liquidity and capital resources and other financial and operating information. When used in this discussion, the words "may," "believes," "intends," "seeks," "anticipates," "plans," "estimates," "expects," "should," "assumes," "continues," "could," "will," "future" and the negative of these or similar terms and phrases are intended to identify forward-looking statements. Forward-looking statements are subject to a number of risks and uncertainties, many of which involve factors or circumstances that are beyond the control of the company. The company's actual results could differ materially from those stated or implied in forward-looking statements due to a number of factors, including but not limited to, the continued availability of tax-advantaged consumer-directed benefits to employers and employees, the company's ability to acquire and retain new network partners and to cross-sell its products to existing network partners and members, the company's ability to successfully identify, acquire and integrate additional portfolio purchases or acquisition targets, the company's ability to raise awareness among employers and employees about the advantages of adopting and participating in consumer-directed benefits programs, and the company's ability to identify and execute on network partner opportunities. For a detailed discussion of these and other risk factors, please refer to the risks detailed in the company's filings with the Securities and Exchange Commission, including, without limitation, the most recent Annual Report on Form 10-K and subsequent periodic and current reports. Past performance is not necessarily indicative of future results. The company undertakes no intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. These forward-looking statements should not be relied upon as representing the company's views as of any date subsequent to the date of this press release.

HealthEquity, Inc. and its subsidiaries Condensed consolidated balance sheets (unaudited)

| (in thousands, except par value) | | October 31, 2016 | | January 31, 2016 |
|--|----|---------------------------------------|----|------------------|
| Assets | | | | |
| Current assets | | | | |
| Cash and cash equivalents | \$ | 125,346 | \$ | 83,641 |
| Marketable securities, at fair value | | 40,352 | | 40,134 |
| Total cash, cash equivalents and marketable securities | | 165,698 | | 123,775 |
| Accounts receivable, net of allowance for doubtful accounts of \$34 as of October 31, 2016 and \$40 as of January 31, 2016 | | 14,064 | | 14,308 |
| Inventories | | 944 | | 620 |
| Current deferred tax asset | | _ | | 2,642 |
| Other current assets | | 5,352 | | 1,703 |
| Total current assets | | 186,058 | | 143,048 |
| Property and equipment, net | | 5,373 | | 3,506 |
| Intangible assets, net | | 65,688 | | 66,840 |
| Goodwill | | 4,651 | | 4,651 |
| Deferred tax asset | | 696 | | _ |
| Other assets | | 2,003 | | 1,750 |
| Total assets | \$ | 264,469 | \$ | 219,795 |
| Liabilities and stockholders' equity | | · · · · · · · · · · · · · · · · · · · | | · · · · · · |
| Current liabilities | | | | |
| Accounts payable | \$ | 1,582 | \$ | 2,431 |
| Accrued compensation | | 4,659 | | 7,776 |
| Accrued liabilities | | 4,195 | | 1,899 |
| Total current liabilities | | 10,436 | | 12,106 |
| Long-term liabilities | | | | |
| Other long-term liabilities | | 1,295 | | 236 |
| Deferred tax liability | | 149 | | 3,996 |
| Total long-term liabilities | | 1,444 | | 4,232 |
| Total liabilities | | 11,880 | | 16,338 |
| Commitments and contingencies | | | | |
| Stockholders' equity | | | | |
| Preferred stock, \$0.0001 par value, 100,000 shares authorized, no shares issued and outstanding as of October 31, 2016 and January 31, 2016, respectively | | _ | | _ |
| Common stock, \$0.0001 par value, 900,000 shares authorized, 59,306 and 57,726 shares issued and outstanding as of October 31, 2016 and January 31, 2016, respectively | | 6 | | 6 |
| Additional paid-in capital | | 226,794 | | 199,940 |
| Accumulated other comprehensive loss | | (134) | | (98) |
| Accumulated earnings | | 25,923 | | 3,609 |
| Total stockholders' equity | | 252,589 | | 203,457 |
| Total liabilities and stockholders' equity | \$ | 264,469 | \$ | 219,795 |
| | - | | - | |

HealthEquity, Inc. and its subsidiaries Condensed consolidated statements of operations and comprehensive income (unaudited)

| | | Three mon | ths end | led October 31, | Nine months ended October 31 | | | |
|---|----|-----------|---------|-----------------|------------------------------|---------|----|--------|
| (in thousands, except per share data) | | 2016 | | 2015 | | 2016 | | 2015 |
| Revenue: | | | | | | | | |
| Service revenue | \$ | 18,781 | \$ | 15,201 | \$ | 56,610 | \$ | 44,507 |
| Custodial revenue | | 14,967 | | 9,142 | | 43,557 | | 26,592 |
| Interchange revenue | | 9,610 | | 6,213 | | 31,389 | | 19,801 |
| Total revenue | | 43,358 | | 30,556 | | 131,556 | | 90,900 |
| Cost of revenue: | | | | | | | | |
| Service costs | | 12,675 | | 9,395 | | 34,471 | | 26,162 |
| Custodial costs | | 2,461 | | 1,536 | | 7,211 | | 4,471 |
| Interchange costs | | 2,331 | | 1,949 | | 7,748 | | 6,100 |
| Total cost of revenue | | 17,467 | | 12,880 | | 49,430 | | 36,733 |
| Gross profit | | 25,891 | | 17,676 | | 82,126 | | 54,167 |
| Operating expenses: | | | | | | | | |
| Sales and marketing | | 4,391 | | 3,067 | | 12,764 | | 8,637 |
| Technology and development | | 6,209 | | 4,419 | | 15,827 | | 11,941 |
| General and administrative | | 5,166 | | 3,477 | | 15,290 | | 10,578 |
| Amortization of acquired intangible assets | | 1,083 | | 409 | | 3,214 | | 1,227 |
| Total operating expenses | | 16,849 | | 11,372 | | 47,095 | | 32,383 |
| Income from operations | | 9,042 | | 6,304 | | 35,031 | | 21,784 |
| Other expense: | | | | | | | | |
| Other expense, net | | (256) | | 121 | | (934) | | (526) |
| Total other expense | | (256) | | 121 | | (934) | | (526) |
| Income before income taxes | | 8,786 | | 6,425 | | 34,097 | | 21,258 |
| Income tax provision | | 2,778 | | 2,338 | | 11,783 | | 7,773 |
| Net income | \$ | 6,008 | \$ | 4,087 | \$ | 22,314 | \$ | 13,485 |
| Net income per share: | | | | | | | | |
| Basic | \$ | 0.10 | \$ | 0.07 | \$ | 0.38 | \$ | 0.24 |
| Diluted | \$ | 0.10 | \$ | 0.07 | \$ | 0.37 | \$ | 0.23 |
| Weighted-average number of shares used in computing net income per share: | | | | | | | | |
| Basic | | 58,938 | | 57,353 | | 58,338 | | 56,397 |
| Diluted | | 60,073 | | 59,263 | | 59,693 | | 58,664 |
| Comprehensive income: | | | | | | | | |
| Net income | \$ | 6,008 | \$ | 4,087 | \$ | 22,314 | \$ | 13,485 |
| Other comprehensive loss: | | | | | | | | |
| Unrealized loss on available-for-sale marketable securities, net of tax | | (23) | | (34) | | (36) | | (67) |
| Comprehensive income | \$ | 5,985 | \$ | 4,053 | \$ | 22,278 | \$ | 13,418 |

HealthEquity, Inc. and its subsidiaries Condensed consolidated statements of cash flows (unaudited)

| (in thousands) 2016 Cash flows from operating activities: Adjustments to reconcile net income to net cash provided by operating activities: Depreciation and amortization 9,543 Admontization of deferred financing costs 5.3 Deferred taxes (1,880) Stock-based compensation 6,399 Changes in operating assets and liabilities: (2,244) Inventories (3,244) Other assets (3,955) Accounts receivable (3,955) Accound compensation (3,117) Accured compensation (3,117) Accured compensation (3,117) Accured compensation (3,117) Accured fiabilities 1,066 Other assets (2,75) Purchase of property and equipment (2,75) Purchase of property and equipment (2,75) Purchase of order investing activities: (6,799) Purchase of order investing activities (6,799) Purchase of order investing activities (9,779) Cash flow from investing activities (9,779) | ctober 31 |
|--|-----------|
| Net income \$ 22.314 \$ Adjustments to reconcile net income to net cash provided by operating activities: 9.543 Amoritzation and amoritzation 9.543 Amoritzation of deferred financing costs 53 Deferred taxes (1.880) Stock-based compensation 6.399 Changes in operating assets and liabilities: (324) Accounts receivable (3.955) Accounts receivable (3.955) Account compensation (3.17) Accrued compensation (3.17) Accrued compensation 1.066 Other non-term liabilities 1.069 Purchases of marketable securities (2.75) Purchase of property and equipment (2.75) Purchase of other investing activities: (6.79) Purchase of other investing activities: (9.77) Purchase of other investing activities: <th>201</th> | 201 |
| Adjustments to reconcile net income to net cash provided by operating activities: 9,543 Depreciation and amoritzation 9,543 Amoritzation of deferred financing costs 53 Deferred taxes (1,880) Stock-based compensation 6,399 Changes in operating assets and liabilities: 244 Inventories (324) Other assets (3355) Accounts receivable (973) Accounts receivable (3,117) Accured compensation (3,117) Accured tabilities 1,066 Other asset payable (0,73) Accured remin liabilities 1,059 Vet cash provided by operating activities 31,029 Cash thows from investing activities (2,705) Purchase of property and equipment (2,705) Purchase of other investing activities | |
| Depreciation and amortization 9,543 Amortization of deferred financing costs 53 Deferred taxes (1,880) Stock-based compensation 6,399 Changes in operating assets and liabilities: 244 Inventories (324) Other assets (335) Accounts receivable (373) Accounts payable (973) Accounts payable (3,117) Accounts payable (3,117) Accound billities 1,059 Other assets 1,059 Other long-term liabilities 1,059 Net cash provided by operating activities 31,029 Cash flows from investing activities (2,705) Purchase of norperty and equipment (2,705) Purchase of software and capitalized software development costs (6,799) Purchase of other investing activities | 13,48 |
| Amortization of deferred financing costs 53 Deferred taxes (1,880) Stock-based compensation 6,399 Changes in operating assets and liabilities: 244 Inventories 244 Inventories (3,242) Other assets (3,395) Accounts payable (973) Accrued compensation (3,117) Accrued liabilities (1,666) Other assets 31,029 Cash flows from investing activities: 10,059 Purchase of property and equipment (2,705) Purchase of order and capitalized software development costs (0,779) Purchase of osftware and capitalized software development costs (0,779) Purchase of other investing activities: Purchase of other inves | |
| Deferred taxes (1,880) Stock-based compensation (6,399) Changes in operating assets and liabilities: 244 Inventories (324) Other assets (324) Other assets (324) Accounts provide (373) Accrued compensation (3,117) Accrued compensation (3,117) Accrued compensation (3,117) Accrued iabilities 1,056 Other long-term liabilities 31,029 Cash flows from investing activities 31,029 Cash flows from investing activities (2,705) Purchase of property and equipment (2,705) Purchase of software and capitalized software development costs (6,799) Purchase of software and capitalized software development costs (9,779) Cash flows from financing activities: - Proceeds from follow-on offering, net of payments for offering costs - Proceeds from follow-on offering, net of payments for offering costs - Proceeds from follow-on offering, net of payments for offering costs - Proceeds from follow-on offering, net of payments | 5,73 |
| Stock-based compensation6,399Changes in operating assets and liabilities:Accounts receivable244Inventories(324)Other assets(3,955)Accounts payable(973)Accrued compensation(3,117)Accrued liabilities1,666Other long-term liabilities1,059Vet cash provided by operating activities31,029Cash flows from investing activities(275)Purchase of marketable securities(275)Purchase of software and capitalized software development costs(6,799)Purchase of other investments-Act cash used in investing activities-Purchase of other investments-Proceeds from financing activities(9,779)Purchase of common stock options4,546Tax benefit from exercise of common stock options15,909Defered financing costs paid-Vet cash provided by financing activities20,455Increase (decrease) in cash and cash equivalents-At cash provided by financing activities-At cash provided b | - |
| Changes in operating assets and liabilities: 244 Accounts receivable 244 Inventories (324) Other assets (3955) Accounts payable (973) Accrued compensation (3.117) Accrued liabilities 1.666 Other assets 31.029 Cash provided by operating activities: 31.029 Purchase of marketable securities (2.75) Purchase of property and equipment (2.705) Purchase of property and equipment (2.705) Purchase of other investments - Acquisition of intangible member assets - Vet cash used in investing activities: - Proceeds from follow-on offering, net of payments for offering costs - Proceeds from follow-on offering, net of payments for offering costs - Proceeds from exercise of common stock options 15.909 Defered financing activities - Vet cash provided by financing activities - Tax benefit from exercise of common stock options 15.909 Defered financing activities - Tax benefit from exercise of common stock options 4.546 < | (1,50 |
| Accounts receivable 244 Inventories (324) Other assets (3955) Accounts payable (973) Accounts domestion (3,117) Accrued liabilities 1,666 Other long-term liabilities 1,666 Other long-term liabilities 31,029 Cash flows from investing activities 31,029 Cash flows from investing activities (2,705) Purchase of property and equipment (2,705) Purchase of software and capitalized software development costs (6,799) Purchase of other investments – Acquisition of intangible member assets – Net cash used in investing activities: – Proceeds from follow-on offering, net of payments for offering costs – Proceeds from follow-on offering, net of payments for offering costs – Proceeds from exercise of common stock options 15,909 Deferred financing activities – Net cash provided by financing activities – Rest ash provided by financing activities 20,455 Increase (decrease) in cash and cash equivalents < | 4,25 |
| Inventories(324)Other assets(3,955)Accounts payable(973)Accrued compensation(3,117)Accrued liabilities1,666Other long-term liabilities1,059Net cash provided by operating activities:31,029Purchases of marketable securities(275)Purchases of property and equipment(2,705)Purchase of software and capitalized software development costs(6,799)Purchase of other investing activities:-Acquisition of intangible member assets-Acquisition of intangible member assets-Proceeds from follow-on offering, net of payments for offering costs-Proceeds from exercise of common stock options15,909Deferred financing activities-Net cash provided by financing activities-Proceeds from exercise of common stock options15,909Deferred financing activities-Net cash provided by financing activities-Recease in cash and cash equivalents20,455Beginning cash and cash equivalents83,641 | |
| Other assets(3,95)Accounts payable(973)Accrued compensation(3,117)Accrued iabilities(3,66)Other long-term liabilities1,659Other long-term liabilities31,029Cash flows from investing activities:(2,75)Purchases of marketable securities(2,705)Purchase of software and capitalized software development costs(6,79)Purchase of other investments-Acquisition of intangible member assets-Acquisition of intangible member assets-Proceeds from follow-on offering, net of payments for offering costs-Proceeds from exercise of common stock options15,909Deferred financing activities-Net cash provided by financing activities-Proceeds from exercise of common stock options15,909Deferred financing activities-Cash envided by financing activities-Tax benefit from exercise and cash equivalents20,455Increase (decrease) in cash and cash equivalents41,705Beginning cash and cash equivalents83,641 | (86 |
| Accounts payable(973)Accrued compensation(3,117)Accrued compensation(3,117)Accrued liabilities1,666Other long-term liabilities1,059Vet cash provided by operating activities31,029Sach flows from investing activities:(275)Purchases of marketable securities(275)Purchase of property and equipment(2,705)Purchase of software and capitalized software development costs(6,799)Purchase of other investments-Acquisition of intangible member assets-Vet cash used in investing activities:(9,779)Cash flows from financing activities:-Proceeds from follow-on offering, net of payments for offering costs-Proceeds from exercise of common stock options15,909Deferred financing costs paid-Vet cash provided by financing activities-Incase (decrease) in cash and cash equivalents41,705Beginning cash and cash equivalents83,641 | (19 |
| Accrued compensation(3,117)Accrued liabilities1,666Other long-term liabilities1,059Vet cash provided by operating activities31,029Cash flows from investing activities(275)Purchases of marketable securities(275)Purchase of property and equipment(2,705)Purchase of software and capitalized software development costs(6,799)Purchase of other investments–Acquisition of intangible member assets–Vet cash used in investing activities(9,779)Cash flows from financing activities–Proceeds from follow-on offering, net of payments for offering costs–Proceeds from exercise of common stock options4,546Tax benefit from exercise of common stock options15,909Deferred financing activities–Vet cash provided by financing activities–Vet cash provided by financing activities20,455Increase (decrease) in cash and cash equivalents41,705Beginning cash and cash equivalents83,641 | (1,42 |
| Accrued liabilities1,666Other long-term liabilities1,059Net cash provided by operating activities31,029Cash flows from investing activities:(275)Purchases of marketable securities(275)Purchase of property and equipment(2,705)Purchase of software and capitalized software development costs(6,799)Purchase of other investmentsAcquisition of intangible member assetsNet cash used in investing activities:(9,79)Proceeds from financing activities:Proceeds from exercise of common stock options4,546Tax benefit from exercise of common stock options15,909Deferred financing activitiesNet cash provided by financing activitiesProceeds from exercise of common stock options15,909Deferred financing activitiesNet cash provided by financing activitiesSeginning cash and cash equivalentsSeginning cash and cas | 41 |
| Other long-term liabilities1,059Net cash provided by operating activities31,029Cash flows from investing activities:(275)Purchases of marketable securities(2705)Purchase of property and equipment(2,705)Purchase of software and capitalized software development costs(6,799)Purchase of other investmentsAcquisition of intangible member assetsNet cash used in investing activities(9,779)Cash flows from financing activitiesProceeds from follow-on offering, net of payments for offering costsProceeds from exercise of common stock options15,909Deferred financing costs paidNet cash provided by financing activities20,455Increase (decrease) in cash and cash equivalents41,705Beginning cash and cash equivalents43,641 | (1,40 |
| Vet cash provided by operating activities31,029Cash flows from investing activities:(275)Purchases of marketable securities(2705)Purchase of property and equipment(2,705)Purchase of software and capitalized software development costs(6,799)Purchase of other investments—Acquisition of intangible member assets—Vet cash used in investing activities:(9,779)Proceeds from financing activities:—Proceeds from follow-on offering, net of payments for offering costs—Proceeds from exercise of common stock options4,546Tax benefit from exercise of common stock options15,909Deferred financing activities—Vet cash provided by financing activities41,705Seginning cash and cash equivalents83,641 | 56 |
| Cash flows from investing activities:Purchases of marketable securities(275)Purchase of property and equipment(2,705)Purchase of software and capitalized software development costs(6,799)Purchase of other investments—Acquisition of intangible member assets—Acquisition of intangible member assets—Vet cash used in investing activities:—Proceeds from follow-on offering, net of payments for offering costs—Proceeds from exercise of common stock options15,909Deferred financing costs paid—Net cash provided by financing activities—Increase (decrease) in cash and cash equivalents41,705Beginning cash and cash equivalents83,641 | (29 |
| Purchases of marketable securities(275)Purchase of property and equipment(2,705)Purchase of software and capitalized software development costs(6,799)Purchase of other investments—Acquisition of intangible member assets—Vet cash used in investing activities(9,779)Proceeds from follow-on offering, net of payments for offering costs—Proceeds from follow-on offering, net of payments for offering costs—Proceeds from exercise of common stock options15,909Deferred financing costs paid—Net cash provided by financing activities—Increase (decrease) in cash and cash equivalents41,705Beginning cash and cash equivalents83,641 | 18,77 |
| Purchase of property and equipment(2,705)Purchase of software and capitalized software development costs(6,799)Purchase of other investments—Acquisition of intangible member assets—Acquisition of intangible member assets—Vet cash used in investing activities(9,779)Cash flows from financing activities:—Proceeds from follow-on offering, net of payments for offering costs—Proceeds from exercise of common stock options4,546Tax benefit from exercise of common stock options15,909Deferred financing costs paid—Vet cash provided by financing activities20,455Increase (decrease) in cash and cash equivalents41,705Beginning cash and cash equivalents83,641 | |
| Purchase of software and capitalized software development costs(6,799)Purchase of other investments—Acquisition of intangible member assets—Acquisition of intangible member assets—Net cash used in investing activities(9,779)Cash flows from financing activities:—Proceeds from follow-on offering, net of payments for offering costs—Proceeds from exercise of common stock options4,546Tax benefit from exercise of common stock options15,909Deferred financing costs paid—Net cash provided by financing activities20,455ncrease (decrease) in cash and cash equivalents41,705Beginning cash and cash equivalents83,641 | (40,21 |
| Purchase of other investments — Acquisition of intangible member assets — Acquisition of intangible member assets — Net cash used in investing activities (9,779) Cash flows from financing activities: — Proceeds from follow-on offering, net of payments for offering costs — Proceeds from exercise of common stock options 4,546 Tax benefit from exercise of common stock options 15,909 Deferred financing costs paid — vet cash provided by financing activities 20,455 ncrease (decrease) in cash and cash equivalents 41,705 Beginning cash and cash equivalents 83,641 | (1,88 |
| Acquisition of intangible member assets | (4,75 |
| Net cash used in investing activities (9,779) Cash flows from financing activities: - Proceeds from follow-on offering, net of payments for offering costs - Proceeds from exercise of common stock options 4,546 Tax benefit from exercise of common stock options 15,909 Deferred financing costs paid - Net cash provided by financing activities 20,455 ncrease (decrease) in cash and cash equivalents 41,705 Beginning cash and cash equivalents 83,641 | (50 |
| Cash flows from financing activities:Proceeds from follow-on offering, net of payments for offering costs—Proceeds from exercise of common stock options4,546Tax benefit from exercise of common stock options15,909Deferred financing costs paid—Vet cash provided by financing activities20,455Increase (decrease) in cash and cash equivalents41,705Beginning cash and cash equivalents83,641 | (33,82 |
| Proceeds from follow-on offering, net of payments for offering costs—Proceeds from exercise of common stock options4,546Tax benefit from exercise of common stock options15,909Deferred financing costs paid—Net cash provided by financing activities20,455ncrease (decrease) in cash and cash equivalents41,705Beginning cash and cash equivalents83,641 | (81,17 |
| Proceeds from exercise of common stock options 4,546 Tax benefit from exercise of common stock options 15,909 Deferred financing costs paid — Net cash provided by financing activities 20,455 ncrease (decrease) in cash and cash equivalents 41,705 Beginning cash and cash equivalents 83,641 | |
| Proceeds from exercise of common stock options4,546Tax benefit from exercise of common stock options15,909Deferred financing costs paid—Net cash provided by financing activities20,455ncrease (decrease) in cash and cash equivalents41,705Beginning cash and cash equivalents83,641 | 23,49 |
| Tax benefit from exercise of common stock options15,909Deferred financing costs paid—Vet cash provided by financing activities20,455Increase (decrease) in cash and cash equivalents41,705Beginning cash and cash equivalents83,641 | 1,75 |
| Net cash provided by financing activities20,455Increase (decrease) in cash and cash equivalents41,705Beginning cash and cash equivalents83,641 | 11,31 |
| ncrease (decrease) in cash and cash equivalents41,705Beginning cash and cash equivalents83,641 | (15 |
| ncrease (decrease) in cash and cash equivalents41,705Beginning cash and cash equivalents83,641 | 36,40 |
| Beginning cash and cash equivalents 83,641 | (25,99 |
| Ending cash and cash equivalents \$ 125,346 \$ | 111,00 |
| | 85,00 |
| Supplemental disclosures of non-cash investing and financing activities: | |
| Purchases of property and equipment included in accounts payable or accrued liabilities at period end \$ 569 \$ | 22 |
| Purchases of software and capitalized software development costs included in accounts payable or accrued liabilities at period end 185 | 21 |
| Deferred financing costs — | 15 |

Stock-based compensation expense

Total stock-based compensation expense included in the condensed consolidated statements of operations and comprehensive income is as follows:

| | | Three months ended October 31, | | | | Nine months ended October 31, | | |
|--|----|--------------------------------|----|-------|----|-------------------------------|----|-------|
| (in thousands) | | 2016 | | 2015 | | 2016 | | 2015 |
| Cost of revenue | \$ | 462 | \$ | 304 | \$ | 1,258 | \$ | 740 |
| Sales and marketing | | 364 | | 218 | | 930 | | 705 |
| Technology and development | | 487 | | 290 | | 1,290 | | 677 |
| General and administrative | | 755 | | 671 | | 2,921 | | 2,132 |
| Total stock-based compensation expense | \$ | 2,068 | \$ | 1,483 | \$ | 6,399 | \$ | 4,254 |

HSA Members

| | October 31, 2016 | October 31, 2015 | % Change | January 31, 2016 |
|---------------------------------------|------------------|------------------|----------|------------------|
| HSA Members | 2,378,353 | 1,602,156 | 48% | 2,140,631 |
| Average HSA Members - Year-to-date | 2,278,994 | 1,516,821 | 50% | 1,600,327 |
| Average HSA Members - Quarter-to-date | 2,354,227 | 1,580,482 | 49% | 1,850,843 |
| HSA Members with investments | 58,226 | 40,695 | 43% | 44,680 |

Assets under management (AUM)

| (in thousands, except percentages) | October 31, 2016 | October 31, 2015 | % Change | January 31, 2016 |
|--|------------------|------------------|----------|------------------|
| Cash AUM | \$ 3,713,290 | \$ 2,307,914 | 61% | \$ 3,278,628 |
| Investment AUM | 570,553 | 385,243 | 48% | 405,878 |
| Total AUM | \$ 4,283,843 | \$ 2,693,157 | 59% | \$ 3,684,506 |
| Average daily cash AUM - Year-to-date | \$ 3,596,571 | \$ 2,207,732 | 63% | \$ 2,326,506 |
| Average daily cash AUM - Quarter-to-date | \$ 3,669,480 | \$ 2,269,253 | 62% | \$ 2,682,827 |

Reconciliation of net income to Adjusted EBITDA

| | Three months ended October 31, | | | | | Nine months ended October 31, | | |
|--|--------------------------------|----|-------|----|--------|-------------------------------|--------|--|
| (in thousands) | 2016 | | 2015 | | 2016 | | 2015 | |
| Net income | \$ 6,008 | \$ | 4,087 | \$ | 22,314 | \$ | 13,485 | |
| Interest income | (137) | | (116) | | (385) | | (302) | |
| Interest expense | 69 | | 23 | | 206 | | 23 | |
| Income tax provision | 2,778 | | 2,338 | | 11,783 | | 7,773 | |
| Depreciation and amortization | 2,335 | | 1,656 | | 6,329 | | 4,503 | |
| Amortization of acquired intangible assets | 1,083 | | 409 | | 3,214 | | 1,227 | |
| Stock-based compensation expense | 2,068 | | 1,483 | | 6,399 | | 4,254 | |
| Other (1) | 323 | | (29) | | 1,113 | | 804 | |
| Adjusted EBITDA | \$ 14,527 | \$ | 9,851 | \$ | 50,973 | \$ | 31,767 | |

(1) For the three months ended October 31, 2016 and 2015, Other consisted of non-income-based taxes of \$86 and \$77, other costs of \$237 and \$81, and acquisition-related costs of \$0 and \$(187) respectively. For the nine months ended October 31, 2016 and 2015, Other consisted of non-income-based taxes of \$260 and \$249, acquisition-related costs of \$595 and \$474, and other costs of \$258 and \$81, respectively.

Reconciliation of net income outlook to adjusted EBITDA outlook

| | For the year ending |
|--|---------------------|
| (in millions) | January 31, 2017 |
| Net income | \$23 - 25 |
| Income tax provision | 13 - 14 |
| Depreciation and amortization | ~ 9 |
| Amortization of acquired intangible assets | ~ 4 |
| Stock-based compensation expense | ~ 9 |
| Other | ~ 1 |
| Adjusted EBITDA | \$59 - 62 |